Key Breast Journal Articles - Targeted Agents

Treatment of Metastatic ErbB2-positive Breast Cancer: Options After Progression On Trastuzumab
N Spector
Clin Breast Cancer. Mar 2008; 8 Suppl 3:S94-9
Journal | Pubmed

Cardiac Management during Adjuvant Trastuzumab Therapy: Recommendations of the Canadian Trastuzumab Working Group
JR Mackey, M Clemons, MA Cote, D Delgado, S Dent, A Paterson, L Provencher, MB Sawyer, & S Verma.
Curr Oncol. Jan 2008; 15(1):24-35
Journal | Pubmed

Bevacizumab for Advanced Breast Cancer
TA Traina, HS Rugo, & M Dickler
Hematol Oncol Clin North Am. Apr 2007; 21(2):303-319
Journal | Pubmed

Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
CE Geyer, J Forster, D Lindquist, S Chan, CG Romieu, T Pienkowski, A Jagiello-Gruszfeld, J Crown, A Chan, B Kaufman, D Skarlos, M Campone, N Davidson, M Berger, C Oliva, SD Rubin, S Stein, & D Cameron
NEJM. Dec 28 2006; 355(26):2733-43
Journal | Pubmed

Management of HER2-Positive Breast Cancer
EP Winer, MJ Piccart-Gebhart, HS Rugo, & GW Sledge Jr
ASCO 2006 Educational Book
Journal

Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer
H Joensuu, PL Kellokumpu-Lehtinen, P Bono, T Alanko, V Kataja, R Asola, T Utriainen, R Kokko, A Hemminki, M Tarkkanen, T Turpeenniemi-Hujanen, S Jyrkkiö, M Flander, L Helle, S Ingalsuo, K Johansson, AS Jääskeläinen, M Pajunen, M Rauhala, J Kaleva-Kerola, T Salminen, M Leinonen, I Elomaa, & J Isola; for the FinHer Study Investigators
NEJM. Feb 23 2006; 354(8):809-20
Journal | Pubmed

Herceptin and the Heart -- A Molecular Modifier of Cardiac Failure
KR Chien
NEJM. Feb 23 2006; 354(8):789-90
Journal | Pubmed

Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
MJ Piccart-Gebhart, M Procter, B Leyland-Jones, A Goldhirsch, M Untch, I Smith, L Gianni, J Baselga, R Bell, C Jackisch, D Cameron, M Dowsett, CH Barrios, G Steger, CS Huang, M Andersson, M Inbar, M Lichinitser, I Láng, U Nitz, H Iwata, C Thomssen, C Lohrisch, TM Suter, J Rüschoff, T Süt, V Greatorex, C Ward, C Straehle, E McFadden, MS Dolci, & RD Gelber; for the Herceptin Adjuvant (HERA) Trial Study Team
NEJM. Oct 20 2005; 353(16):1659-72
Journal | Pubmed

Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
EH Romond, EA Perez, J Bryant, VJ Suman, CE Geyer Jr, NE Davidson, E Tan-Chiu, S Martino, S Paik, PA Kaufman, SM Swain, TM Pisansky, L Fehrenbacher, LA Kutteh, VG Vogel, DW Visscher, G Yothers, RB Jenkins, AM Brown, SR Dakhil, EP Mamounas, WL Lingle, PM Klein, JN Ingle, & N Wolmark
NEJM. Oct 20 2005; 353(16):1673-84
Journal | Pubmed

Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer
CL Vogel, MA Cobleigh, D Tripathy, JC Gutheil, LN Harris, L Fehrenbacher, DJ Slamon, M Murphy, WF Novotny, M Burchmore, S Shak, SJ Stewart, & M Press
JCO. Feb 1 2002; 20(3):719-26
Journal | Pubmed

Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
DJ Slamon, B Leyland-Jones, S Shak, H Fuchs, V Paton, A Bajamonde, T Fleming, W Eiermann, J Wolter, M Pegram, J Baselga, & L Norton
NEJM. Mar 15 2001; 344(11):783-92
Journal | Pubmed